AG真人官方

Form 8-K, Item 7.01 鈥� Regulation FD. On 31 Jul 2025 Silexion Therapeutics Corp (SLXN) furnished a press release titled 鈥淪ilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation.鈥� The release describes laboratory findings that achieved up to 97 % inhibition of cancer-cell proliferation and activity against a novel KRAS mutation.

The disclosure is expressly 鈥渇urnished鈥� rather than 鈥渇iled,鈥� shielding it from Exchange Act 搂18 liability and preventing automatic incorporation into Securities Act filings. No financial metrics, clinical-trial results, regulatory milestones, or transactional details accompanied the announcement. Exhibit 99.1 contains the press release; Exhibit 104 is the Inline XBRL cover page. Ordinary shares (SLXN) and high-strike warrants (SLXNW) remain listed on Nasdaq.

Investor takeaway: Encouraging preclinical signal but very early in the development cycle; there is no immediate effect on revenue, guidance, or balance-sheet items.

On 31 July 2025, a Form 144 filing for Argan, Inc. (AGX) indicates the proposed sale of 1,604 common shares through broker Raymond James. The shares, valued at an aggregate $384,960, were obtained on 30 July 2025 via an equity-grant/option exercise. With 13.64 million shares outstanding, the planned sale equals roughly 0.012 % of the float, implying a modest personal liquidation rather than a sizable insider exit. The filing also shows that Richard Deily鈥攏amed in the past-sales section鈥攕old 1,565 shares for $238,381 on 30 Apr 2025. No earnings data or corporate updates accompany the notice, and the signer affirms no undisclosed adverse information. Given the limited volume and routine nature of Rule 144 transactions, the event appears largely immaterial to AGX鈥檚 fundamentals or near-term valuation.

Silexion Therapeutics (SLXN) filed an 8-K announcing a 1-for-15 reverse share split effective after the 28-Jul-25 close. Authorized capital stays US$20,000 but is now divided into 1,481,482 ordinary shares; par value rises to US$0.0135. All issued and outstanding shares are reduced proportionally and will begin trading on a split-adjusted basis under the same ticker at the 29-Jul-25 open. The new ordinary-share CUSIP is G1281K 130.

The company simultaneously delivered a Warrant Adjustment Notice. Each pre-split warrant is now exercisable for 1/15th of a share, and the exercise price is lifted 15脳 to US$1,552.50 per post-split share. Fractional entitlements will be rounded up at the broker (DTC participant) level. Warrant CUSIP (G1281K 114) and ticker (SLXNW) are unchanged.

The split was approved at the 14-Jul-25 AGM and effected through an amendment to the Amended & Restated Memorandum of Association, filed 28-Jul-25. Items 3.03 and 5.03 detail the warrant modifications and charter amendment, while Item 8.01 incorporates these events by reference.

Nova Minerals Limited (NVA) filed a Form 6-K detailing the completion of its U.S. initial public offering of American Depositary Shares (ADS).

• The company entered an underwriting agreement on 14 Jul 2025 with ThinkEquity to sell 1,200,000 ADS (1 ADS = 60 ordinary shares) at $9.25 per ADS, generating gross proceeds of $11.1 million.
• Underwriters received a 45-day option for up to 120,000 additional ADSs. They partially exercised the option on 17 Jul 2025, purchasing 108,400 ADS at the same price.
• Closing of the over-allotment occurred on 18 Jul 2025, lifting total gross proceeds to $12.21 million before underwriting discounts and offering expenses.
• The filing contains no information on use of proceeds, dilution magnitude or updated guidance.

The report is furnished, not filed, under the Exchange Act and is not incorporated by reference unless specifically stated in future filings.

Silexion Therapeutics Corp (SLXN) will hold an extraordinary general meeting in Aug-2025 to vote on a single item: increasing authorised share capital to US$121,500 divided into 9,000,000 ordinary shares (par US$0.0135) from the post-reverse-split level of 1,481,482 shares.

The board says the extra 7.5 m shares are essential to (1) regain and thereafter maintain compliance with Nasdaq Listing Rule 5550(b)(1) 鈥� minimum US$2.5 m shareholders鈥� equity by 19-Sep-2025 鈥� following a favourable Nasdaq hearings-panel decision on 7-Jul-2025, and (2) fund pre-clinical/clinical RNAi programs and potential business-development deals. Current capacity is only 529,302 unissued shares, viewed as inadequate for equity raises, warrant/option exercises, conversion of a US$3.433 m sponsor note and employee incentives.

The proposed authorisation represents a 507% increase in total authorised shares. The board unanimously recommends voting FOR. Failure would likely trigger Nasdaq delisting. Risks highlighted include substantial dilution, potential share-price pressure and anti-takeover uses of the new shares.

On July 16 2025 Silexion Therapeutics Corp ("SLXN") filed an 8-K announcing a 1-for-15 reverse share split affecting all issued, outstanding and authorized ordinary shares. The split will be effected automatically after market close on 28 Jul 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq at the open on 29 Jul 2025; the ticker remains "SLXN".

• Every 15 existing shares convert into 1 new share.
• Par value increases from $0.0009 to $0.0135 per share.
• No fractional shares will be issued; DTC positions will be rounded up to the nearest whole share.

The Board鈥檚 goal is to raise the per-share price to maintain compliance with Nasdaq Capital Market listing standards. Warrants ("SLXNW") are expected to be adjusted pursuant to their terms. Additional details are provided in the press release attached as Exhibit 99.1.

Form 3 snapshot: On 07/07/2025, Singapore-based investor Yip Tsz Yan purchased a majority interest in A SPAC II (Holdings) Corp. (鈥淪ponsor鈥�), giving her indirect voting and investment control over the Sponsor鈥檚 stake in A SPAC II Acquisition Corp. (ASUUF). The filing classifies Yip as a 10 % beneficial owner of the issuer.

• Ordinary shares held (indirect): 5,000,000
• Warrants held (indirect): to acquire 8,966,000 Class A ordinary shares
• Exercise price: $11.50 per share
• Warrant timing: Exercisable on the later of (i) completion of the SPAC鈥檚 initial business combination or (ii) 05/02/2023; expire five years after a business combination

The disclosure signals a change in the controlling ownership of the Sponsor, consolidating significant influence over the SPAC鈥檚 future merger decisions. If fully exercised, the warrants could add cash at $11.50 per share but would increase the share count by up to 8.97 million, creating potential dilution for existing holders.

Silexion Therapeutics Corp (NASDAQ: SLXN) filed a Form 8-K on 9 July 2025 under Item 7.01 (Regulation FD). The sole purpose of the filing is to furnish 鈥� not file 鈥� a press release (Exhibit 99.1) titled 鈥淪ilexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines.鈥� No additional financial statements or transaction details are included, and the company explicitly states the information is not incorporated by reference into other Securities Act filings.

Key points

• The press release reports positive preclinical efficacy for SIL204 in human lung cancer cell lines.
• The disclosure is furnished under Regulation FD, ensuring simultaneous public access to the information.
• No revenue, cost, guidance, or clinical-stage data accompany the announcement.
• Exhibits attached: 99.1 (press release) and 104 (Inline XBRL cover data).

Investors receive confirmation of encouraging scientific data but must consult Exhibit 99.1 for experimental specifics, as the 8-K itself contains minimal detail.

Silexion Therapeutics Corp (SLXN) has filed an amended Form 8-K to clarify timing details surrounding its Nasdaq listing status.

The Nasdaq hearings panel has granted the company continued listing but will transfer the ordinary shares and warrants from the Nasdaq Global Market to the Nasdaq Capital Market as soon as practicable. While the original filing stated the move could occur on 8 July 2025, the amendment notes the exact date remains uncertain.

Silexion also warns it may become non-compliant with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price) if its shares close below that threshold for 30 straight trading days. Management intends to cure any deficiency through a 1-for-15 reverse share split, subject to shareholder approval at the reconvened AGM on 14 July 2025. After approval, a mandatory 10-day Nasdaq notice period would push the split to roughly 25 July 2025, with compliance only achieved after the stock trades above $1.00 for 10 consecutive days鈥攑lacing the earliest compliance window in early-to-mid August 2025.

The company cautions that there is no assurance shareholders will approve the split or that the post-split price will meet Nasdaq requirements, leaving a continued risk of delisting.